Skip to content
Ayvakit, Ayvakyt(avapritinib)
Ayvakit, Ayvakyt (avapritinib) is a small molecule pharmaceutical. Avapritinib was first approved as Ayvakit on 2020-01-09. It is used to treat gastrointestinal stromal tumors in the USA. It has been approved in Europe to treat gastrointestinal stromal tumors. It is known to target mast/stem cell growth factor receptor Kit.
Download report
Favorite
FDA Novel Drug Approvals 2020
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
Trade Name
FDA
EMA
Ayvakit
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Avapritinib
Tradename
Company
Number
Date
Products
AYVAKITBlueprint MedicinesN-212608 RX2020-01-09
5 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
ayvakitNew Drug Application2020-01-21
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
gastrointestinal stromal tumorsEFO_0000505D046152C49.A
Agency Specific
FDA
EMA
Expiration
Code
AVAPRITINIB, AYVAKIT, BLUEPRINT MEDICINES
2028-06-16ODE-356
2027-01-09ODE-366
2025-01-09NCE
2024-06-16I-863, I-864
Patent Expiration
Patent
Expires
Flag
FDA Information
Avapritinib, Ayvakit, Blueprint Medicines
92000022034-10-15DS, DPU-2726, U-3168
99446512034-10-15DS, DPU-2726, U-3168
99945752034-10-15DS, DPU-2726, U-3168
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EX: Other protein kinase inhibitors in atc
— L01EX18: Avapritinib
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A311138
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Systemic mastocytosisD034721C96.2112——14
Mast-cell leukemiaD007946C94.311——13
NeoplasmsD009369C8021———2
Hematologic neoplasmsD019337—1——12
Colorectal neoplasmsD015179—1———1
Breast neoplasmsD001943EFO_0003869C50—1———1
Lung neoplasmsD008175C34.90—1———1
SarcomaD012509—1———1
Central nervous system neoplasmsD016543—1———1
MelanomaD008545—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAVAPRITINIB
INNavapritinib
Description
Avapritinib, sold under the brand name Ayvakit among others, is a medication used for the treatment of advanced systemic mastocytosis and for the treatment of tumors due to one specific rare mutation: it is specifically intended for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) that harbor a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation. Avapritinib is a kinase inhibitor.
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Identifiers
PDB—
CAS-ID1703793-34-3
RxCUI2272107
ChEMBL IDCHEMBL4204794
ChEBI ID—
PubChem CID118023034
DrugBankDB15233
UNII ID513P80B4YJ (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KIT
KIT
Organism
Homo sapiens
Gene name
KIT
Gene synonyms
SCFR
NCBI Gene ID
3815
Protein name
mast/stem cell growth factor receptor Kit
Protein synonyms
c-Kit protooncogene, CD117, p145 c-kit, PBT, Piebald trait protein, Proto-oncogene c-Kit, proto-oncogene tyrosine-protein kinase Kit, Tyrosine-protein kinase Kit, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene-like protein
Uniprot ID
Q9UM99
Mouse ortholog
Kit (16590)
mast/stem cell growth factor receptor Kit (Q8C8K9)
Variants
Clinical Variant
No data
Financial
Ayvakit - Blueprint Medicines
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 435 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
13,346 adverse events reported
View more details